Aminopyridine Derivatives for Selective Aurora A Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Aurora kinase inhibitors face challenges in selectively targeting Aurora A without affecting Aurora B, leading to reduced efficacy and potential interference with other cancer treatments like paclitaxel, and there is a lack of Aurora A selective drugs.
Innovation Solution
Development of novel aminopyridine derivatives that selectively inhibit Aurora A, allowing for a synergistic action when combined with other antitumor agents, represented by the compound of Formula (I), which can be administered alone or with other antitumor agents to treat cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Aurora kinase inhibitors are developed to target Aurora A, then antitumor effect is improved, but selectivity between Aurora A and Aurora B is poor due to high homology among subtypes
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at particular positions of the aminopyridine core structure. The compound features specific substitutions at positions 2, 4, and 6 of the pyridine ring, with particular attention to the 4-position amino group and its substituents. This localized modification approach creates distinct binding characteristics that enable selective inhibition of Aurora A over Aurora B, resolving the selectivity problem caused by high homology among kinase subtypes.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types, positions, and configurations on the aminopyridine scaffold. Specific parameters including the nature of R1-R6 substituents, their spatial arrangement, and stereochemical configurations are optimized to achieve differential binding affinity. This parameter optimization enables the compound to maintain high antitumor efficacy while achieving selective inhibition of Aurora A.
2Adaptability or versatility
If dual Aurora A and Aurora B inhibitors are used, then broad kinase inhibition is achieved, but synergistic action with other antitumor agents is reduced
Solution Approach 1:
The patent applies the extraction principle by selectively isolating Aurora A inhibition activity from the dual Aurora A/B inhibition profile. The compound design specifically targets Aurora A while minimizing Aurora B inhibition, thereby extracting the beneficial synergistic effects of Aurora A selectivity. This selective inhibition pattern preserves the synergistic action with paclitaxel and other antitumor agents that was previously attenuated by dual inhibition.
3Reliability
If Aurora A selective inhibitors are developed, then synergistic action with paclitaxel is improved, but drug development complexity increases due to lack of precedents
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development challenge into manageable components: (1) establishing the aminopyridine core structure with proven Aurora kinase inhibition, (2) systematically optimizing substituents at specific positions to achieve Aurora A selectivity, and (3) validating synergistic effects with standard antitumor agents. This segmented approach to structure-activity relationship optimization makes the development of Aurora A selective inhibitors more tractable despite the lack of precedents.
Data Source
AI summary
The present invention relates to a compound of Formula (I):wherein: n is 0 or 1; X is 0 or CH2; R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R10; R5 is H or OCH3; R10 is F or Cl; or a pharmaceutically acceptable salt or ester thereof